LeMaitre Vascular Inc (LMAT) Given Consensus Rating of “Hold” by Analysts
Shares of LeMaitre Vascular Inc (NASDAQ:LMAT) have earned a consensus recommendation of “Hold” from the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $37.33.
Several analysts recently weighed in on LMAT shares. BidaskClub upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, March 9th. Benchmark upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Thursday, April 26th. Zacks Investment Research lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, April 28th. ValuEngine upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, June 15th. Finally, Lake Street Capital began coverage on LeMaitre Vascular in a research note on Monday, June 25th. They issued a “buy” rating and a $45.00 target price on the stock.
In other news, insider Trent G. Kamke sold 12,368 shares of the stock in a transaction on Friday, May 25th. The stock was sold at an average price of $32.83, for a total transaction of $406,041.44. Following the transaction, the insider now owns 20,424 shares of the company’s stock, valued at approximately $670,519.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO George W. Lemaitre sold 8,000 shares of the stock in a transaction on Friday, June 15th. The stock was sold at an average price of $37.04, for a total value of $296,320.00. Following the transaction, the chief executive officer now directly owns 3,073,802 shares in the company, valued at approximately $113,853,626.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 120,598 shares of company stock worth $4,144,663. Insiders own 20.30% of the company’s stock.
NASDAQ:LMAT opened at $35.76 on Wednesday. LeMaitre Vascular has a fifty-two week low of $26.37 and a fifty-two week high of $41.28. The firm has a market cap of $646.58 million, a P/E ratio of 41.58, a P/E/G ratio of 2.05 and a beta of 0.57.
LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Wednesday, April 25th. The medical instruments supplier reported $0.19 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.21 by ($0.02). LeMaitre Vascular had a net margin of 17.34% and a return on equity of 16.66%. The company had revenue of $25.99 million for the quarter, compared to analysts’ expectations of $26.42 million. During the same quarter in the previous year, the company posted $0.16 EPS. The business’s quarterly revenue was up 7.8% on a year-over-year basis. equities analysts forecast that LeMaitre Vascular will post 1.09 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, June 7th. Shareholders of record on Tuesday, May 22nd were paid a $0.07 dividend. The ex-dividend date of this dividend was Monday, May 21st. This represents a $0.28 dividend on an annualized basis and a yield of 0.78%. LeMaitre Vascular’s payout ratio is 32.56%.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.